CTOs on the Move

Bausch + Lomb

www.bausch.com

 
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New ...
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion
  • www.bausch.com
  • 400 Somerset Corporate Boulevard
    Bridgewater, NJ USA 08807
  • Phone: 866.246.8245

Executives

Name Title Contact Details
Manisha Narasimhan
Chief Corporate Development and Digital Officer Profile
Charles Frahm
Executive Director and Chief Security Officer, Bausch and Lomb Profile

Similar Companies

MEDISCA

With over 25 years of experience, MEDISCA has developed a solid reputation as an innovative and entrepreneurial company in the pharmaceutical compounding industry.

Absolute Biotech

Absolute Biotech is a company that specializes in antibody reagents, kits, and services, adding value to existing antibodies through annotation, validation, sequencing, engineering, and recombinant manufacturing.

Innova Primary Care

Innova Primary Care - Mending Standards. Mending People.

National Diabetic Pharmacies

National Diabetic Pharmacies is a Salem, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.